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Improved and targeted delivery of bioactive
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assembled microcapsules
Anton M. Pavlov,†a,b Samantha A. Gabriel,†a Gleb B. Sukhorukov*a and
David J. Gouldc
Despite our increasing knowledge of cell biology and the recognition of an increasing repertoire of drug-
gable intracellular therapeutic targets, there remain a limited number of approaches to deliver bioactive
molecules to cells and even fewer that enable targeted delivery. Layer-by-layer (LbL) microcapsules are
assembled using alternate layers of oppositely charged molecules and are potential cell delivery vehicles
for applications in nanomedicine. There are a wide variety of charged molecules that can be included in
the microcapsule structure including metal nanoparticles that introduce physical attributes. Delivery of
bioactive molecules to cells with LbL microcapsules has recently been demonstrated, so in this study we
explore the delivery of bioactive molecules (luciferase enzyme and plasmid DNA) to cells using bio-
degradable microcapsules containing a layer of magnetite nanoparticles. Interestingly, signiﬁcantly
improved intracellular luciferase enzyme activity (25 fold) and increased transfection eﬃciency with
plasmid DNA (3.4 fold) was observed with magnetic microcapsules. The use of a neodymium magnet
enabled eﬃcient targeting of magnetic microcapsules which further improved the delivery eﬃciency of
the cargoes as a consequence of increased microcapsule concentration at the magnetic site. Micro-
capsules were well tolerated by cells in these experiments and only displayed signs of toxicity at a
capsule : cell ratio of 100 : 1 and with extended exposure. These studies illustrate how multi-functionali-
zation of LbL microcapsules can improve and target delivery of bioactive molecules to cells.
Introduction
LbL assembly is performed under native conditions which are
compatible with the inclusion of bioactive molecules in
assembled microcapsules or other structures such as cellular
coatings.1 Intracellular delivery of bioactive species has tre-
mendous potential for clinical application as well as investi-
gating behaviour of various molecules in their natural state
inside cells.2–5 LbL-assembled microcapsules are interesting
vehicles to use in cell delivery because a variety of biological or
physical properties can endow them with multifunctionality.6,7
Physical characteristics can be added to LbL microcapsules
through inclusion of metal nanoparticles into the shells. Gold
nanoparticles have been employed to trigger intracellular
release of molecules in response to laser-induced heating,8–12
and magnetic nanoparticles have been employed for magneti-
cally controlled targeting. Studies have shown that magnetic
microcapsules can be moved to a magnet,13,14 whilst motor-
ized microcapsules can be directed to a magnet.15 Cellular
studies have demonstrated that ligand bound magnetic micro-
capsules can be employed to sort cancer cells16 and cells with
internalized magnetic microcapsules that are either adherent
or in suspension can be navigated with a magnet.17,18 Whilst
under flow conditions magnetite containing microcapsules
can be magnetically targeted with several microcapsules deli-
vered to each cell.12,19 Despite the potential for magnetic
microcapsules in targeted cell delivery, no study has actually
examined delivery of bioactive cargo molecules in the absence
or presence of a magnetic field.
Delivering bioactive molecules to cells in a targeted manner
remains a challenge in the development of novel therapies.
Proteins encompass a vast range of molecules including
enzymes, hormones, cytokines and transcription factors many
of which act inside cells, yet our ability to deliver proteins to
cells is very limited. Cell penetrating peptides such as the viral
peptides TAT and VP22 have a high percentage of positively†These authors contributed equally.
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charged amino acids and have an ability to directly translocate
across the cell plasma membrane and transport fused proteins
with them, however, this approach indiscriminately targets all
cells unless they are engineered with a targeting moiety.20 The
delivery of nucleic acids to cells uses a wide variety of
approaches for genetic modification of cells in tissue culture
but in vivo delivery is more complex and targeted delivery
relies on the natural tropism of viruses or incorporating anti-
body or peptide targeting domains into chimeric proteins or
lipocomplexes. Microcapsules have the ability to deliver both
proteins and nucleic acids to cells and indeed through their
multifunctionalisation we have demonstrated co-delivery of
both.21 In this study we examined the influence of magnetic
nanoparticles on microcapsule delivery and the ability to mag-
netically target delivery of bioactive molecules.
Materials and methods
Poly-L-arginine hydrochloride (PLA, molecular weight
15–70 kDa), dextran sulfate sodium salt (DS, molecular weight
∼100 kDa), polyethyleneimine, branched (PEI, 25 kDa),
ethylenediaminetetraacetic acid disodium salt (EDTA), sodium
hydroxide, citric acid monohydrate, ammonium hydroxide,
and all salts were purchased from Sigma. Other reagents
included recombinant American firefly luciferase (Roche Diag-
nostics GmbH, Mannheim, Germany), luciferase assay system,
D-luciferin K+ salt from Promega Corp (Madison, WI, USA) and
Dulbecco’s Modified Eagles Media (DMEM), Fetal Bovine
Serum (FBS), penicillin, streptomycin and trypsin were pur-
chased from Lonza.
Plasmid preparation
Plasmid pcLuc+ (ref. 22) encoding firefly luciferase from a
CMV promoter was propagated in DH5α E. coli and was puri-
fied using the Qiagen endofree mega kit (Qiagen Ltd., Crawley,
West Sussex, UK) with plasmid DNA re-suspended in sterile
distilled water.
Magnetic nanoparticles
Magnetite nanoparticles (FeNP) were synthesized according to
the Massart’s precipitation method, followed by particle surface
functionalization with citric acid.23 Briefly, 0.86 g FeCl2 and
2.35 g FeCl3 were dissolved in 40 mL of water and heated to
80 °C under argon in a three-necked flask. While vigorously stir-
ring the reaction mixture, 5 mL of NH4OH was slowly intro-
duced by a syringe and heated for a further 30 min. Next, 1 g of
citric acid dissolved in 2 mL of water was introduced, and the
temperature was raised to 95 °C. Stirring was continued for a
further 90 min. Subsequently, the nanoparticles dispersion was
dialyzed against water in a 12–14 kDa cut-oﬀ cellulose membrane
(Carl Roth, Germany), resulting in a stable dispersion of nega-
tively charged magnetite nanoparticles. Particle size and zeta-
potential were determined via DLS and electrophoretic mobility
measurements, respectively, using Malvern Nano ZS revealing a
mean particle size of 30 nm and a zeta potential of −25 mV.
Size measurement results were also confirmed by TEM imaging
using a JEOL JEM 2010 electron microscope.
Microcapsules
Microcapsules used for experiments were assembled upon
calcium carbonate sacrificial templates, according to a well-
established protocol.24 CaCO3 microparticles were synthesized
by mixing 0.33 M CaCl2 and 0.33 M Na2CO3 solutions at 1 : 1
ratio immediately before use. When luciferase or pcLuc+ were
incorporated into the cores, this was achieved by their co-
precipitation; luciferase or plasmid solutions (at concentration
of 1 mg mL−1) were mixed with CaCl2 prior to Na2CO3
addition. Mass of bioactive compounds used for co-precipi-
tation was kept at ∼200 μg per ml of CaCl2, as this ratio was
used in our previous studies.21,25 After successful core syn-
thesis was verified by optical microscopy, layers were
assembled following the usual LbL procedure.
Layers had a structure of (PLA/DS)3/PEI for non-magnetic
biodegradable microcapsules and (PLA/DS)1.5/FeNP/PLA/DS/
PEI for magnetic biodegradable microcapsules. All polyelectro-
lytes were adsorbed from 2 mg ml−1 solutions. Molarity of
NaCl solution used as the solvent for polyelectrolytes was 0.15
M for biodegradable polyelectrolytes and 0.5 M for PEI. FeNP
incorporation was achieved due to strong electrostatic inter-
action between positively charged groups of PLA and negatively
charged citrate groups of nanoparticles. Nanoparticles were
adsorbed from excess to fully cover the microcapsule surface
to ensure total charge overcompensation which is essential for
successful LbL assembly. An outermost layer of PEI was used
to enhance enzyme activity and plasmid DNA transfection
eﬃciency through promotion of endosomal escape.21,26
After the layers were completed, CaCO3 cores were dissolved
in 0.2 M EDTA solution at pH 6.5. Microcapsules obtained had
a mean diameter of 3–4 μm, as confirmed by SEM imaging.
Microcapsule concentration was measured by haemocytometry
and was adjusted to match the microcapsules : cell ratio
chosen for each experiment. Microcapsules were resuspended
in PBS immediately prior to their addition to cells.
Incorporation ratios of enzyme and plasmids were deter-
mined by measuring the concentration of corresponding
species in supernatants collected from microcapsule synthesis
following the same procedure as described previously.21 Luci-
ferase concentration measurements were performed using an
MLX Microtiter® Plate Luminometer (Dynex Technologies
Inc., USA) and a calibration curve obtained using the solution
of luciferase used for co-precipitation. Plasmid DNA concen-
trations were measured using Qubit™ dsDNA HS Assay Kits
with the Qubit® 2.0 Fluorometer (Invitrogen). Concentration
measurements were performed on centrifuged (4000 rpm,
5 min) solutions. Measured incorporation ratios were similar
to previously reported values.21
Microcapsule structure was characterised by scanning elec-
tron microscopy using FEI Inspect F electron microscope. For
sample preparation, a drop of microcapsule dispersion was
put on top of a small glass slide attached to the sample holder
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and sputtered with gold after drying. Images were taken using
an acceleration voltage of 10 kV.
Cell culture and cell viability tests
The human embryonic kidney epithelial cell line 293T and the
human epithelial carcinoma cell line HeLa were grown in
DMEM supplemented with penicillin (100 U ml−1), strepto-
mycin (100 µg ml−1) glutamine (2 mM) and 10% FBS, in a
humidified incubator containing 10% CO2 at 37 °C.
For cell viability studies HeLa cells were plated at 30 000
cells per well on 96 well plates. The next day microcapsules
were added at ratios of 10 and 100 capsules per cell to tripli-
cate wells and on the subsequent 2 days microcapsules were
added at the same ratios to additional wells. The experiment
was terminated 24 hours later when total incubation times
reached 24, 48 and 72 hours for respective wells. Then 100 µl
titreGLO assay reagent (Promega Corp) was added to each well,
plates were briefly shaken and then incubated for 20 minutes
before the luminescent signal in 1 second was recorded using
a plate luminometer.
Microcapsule delivery to cells
Cells were plated in 24 or 96-well plates at the density
described in individual experiments. The following day 10 μL
of microcapsule suspension was introduced at cell :
microcapsule ratios in the range of 1 : 0.625 to 1 : 10. In experi-
ments investigating the influence of a magnetic field on deliv-
ery, a magnet (25 × 10 × 3 mm thick N42 Neodymium Magnet,
First4Magnets.com, Nottinghamshire, UK) was either placed
under the whole well or the left half of the well during micro-
capsule addition. When a continuous magnetic field was used
a smaller magnet (10 × 3.5 × 2.25 mm thick N45 Neodymium
Magnet, e-magnetsuk.com) was placed under the left side of
the well during addition and it remained in place for the dur-
ation of the experiment.
Sedimentation rate of microcapsules
The rate of sedimentation of magnetic and standard micro-
capsules was monitored using a PerkinElmer Lambda 35
spectrophotometer by measuring absorbance of 3 ml micro-
capsule dispersions at matched concentrations in 4.5 ml
spectrometry cuvettes at 328 nm at regular time intervals. The
wavelength was chosen as a peak for adsorption by magnetic
nanoparticles. To measure the sedimentation rate of magnetic
microcapsules in a magnetic field, the N45 magnet was placed
under the base of the cuvette.
Luciferase activity assay
Cell lysates were prepared from triplicate wells by addition of
passive lysis buﬀer (Promega Corp) for 15 minutes at 37 °C.
Lysates were then collected and stored frozen (−20 °C) until
analysis for enzyme activity. Luciferase activity was monitored
by standard luminometry following addition of 50 µl of luci-
ferase assay reagent (Promega Corp) to cell lysate (10 µl). Light
emission was monitored for 10 seconds following addition of
substrate (50 µl) with an MLX Microtiter® Plate Luminometer
(Dynex Technologies, USA).
Bioluminescence imaging
Real-time bioluminescent imaging was performed with an IVIS
100 system (PerkinElmer Inc. Waltham, MA, USA) which was
used to monitor the uptake of luciferase enzyme containing
microcapsules into 293T cells or their transfection with
plasmid DNA containing microcapsules. These experiments
were performed in black tissue culture plates (Visiplate™ TC,
PerkinElmer Inc.) twenty seconds prior to the imaging 12.5 µl
of D-luciferin K+ salt (Promega Corp) was added to each well,
images were collected without further addition of substrate. A
black and white photo was taken and this was overlaid with a
bioluminescent image. The bioluminescent signal from each
well was quantitated using Living Image software version
2.5.50.1 with values expressed as photons per steradian per
centimetre squared. Where magnetic targeting was used, a
region of interest template was used to determine the bio-
luminescence of each half of the well or in the area where the
magnet was positioned.
Results
Previously we have shown that a middle layer of enzyme or
plasmid DNA sandwiched between polyelectrolytes in the
microcapsule shell is shielded and ineﬀective for delivery to
cells.21,25 However, physical properties have been added to
microcapsules through inclusion of metal nanoparticles in a
middle layer.13 In this study we introduced magnetite nano-
particles as a middle layer of biodegradable microcapsules
which changed their appearance (Fig. 1A and B) but also
increased their density resulting in more rapid sedimentation
from a microcapsule suspension compared to standard micro-
capsules and this sedimentation could be further accelerated
through use of a magnet (Fig. 1C). Importantly, for cell delivery
studies, magnetic microcapsules were well tolerated by cells
and only displayed toxicity after incubation at a ratio of
100 : 1 microcapsules per cell for 48 hours or longer (Fig. 1D).
In view of this observation subsequent cell delivery
experiments utilised a maximum initial microcapsule : cell
ratio of 10 : 1 or lower. Increased density of microcapsules with
magnetic nanoparticles compared to non-magnetic micro-
capsules enhanced their sedimentation rate, resulting in
faster contact of cells with capsules, and hence internalization.
When monitored by real-time bioluminescent imaging
magnetic microcapsules displayed both improved delivery
kinetics and higher maximal delivery of luciferase to cells.
After 240 minutes of incubation magnetic microcapsules
displayed a 25 fold enhancement in delivery of active
luciferase enzyme to cells compared to standard microcapsules
(Fig. 2A and B).
In similar studies, plasmid DNA encoding luciferase
enzyme was delivered with both standard and magnetic micro-
capsules (Fig. 3A and B). Again, these experiments demon-
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strated improved transfection of 293T cells with magnetic
microcapsules (by a factor of 3.4 fold after 72 hours with a
10 : 1 ratio, Fig. 3A and B). Interestingly, when a static magnet
was placed under the whole well during addition of magnetic
microcapsules there was no further enhancement of delivery
(data not shown).
Whilst magnetic attraction per se did not significantly alter
cell transfection with magnetic microcapsules we were also
interested in exploring the potential of microcapsule targeting
with a magnet and studying the eﬀect of this on eﬃciency of
cell delivery. Experiments were performed in wells where the
left-hand side was placed on top of a magnet at the time of
microcapsule addition (Fig. 4A). Experiments with luciferase
enzyme containing microcapsules confirmed the ability to
target magnetic microcapsules to the left-hand side of the well
with significantly more luciferase signal compared to the
right-hand side of these wells (Fig. 4B and C). If all the micro-
capsules navigated to the side of the well where the magnet
was located this would represent a doubling of the micro-
capsule to cell ratio on that side. Indeed, the data in Fig. 4C
generally upholds this hypothesis, with light emission on the
left hand side similar to the light emission from each side of
the well when a 2 fold higher ratio of the microcapsules to
cells was used but without magnetic targeting (Fig. 4C).
We also demonstrated targeted transfection with magnetic
microcapsules. In this experiment transfection with magnetic
and magnet targeted magnetic microcapsules (Fig. 5A) were
compared at two ratios (1 : 1 and 1 : 10). Targeting was again
demonstrated by real-time bioluminescent imaging and is
clearly seen in the displayed image (Fig. 5B) and plotted data
(Fig. 5C). The small magnet (surface area 0.35 cm2) remained
under the well for the duration of the experiment and if all the
delivered microcapsules located in the area of the magnet this
would amount to a concentration increase of 5.4 fold (surface
area of the well was 1.9 cm2). In eﬀect this would equate to a
cell to microcapsule ratio of 1 : 5.4 and 1 : 54 in the area of the
magnet for the 1 : 1 and 1 : 10 ratio wells, respectively. When
the magnet was used, the light emission from its site was 7
fold higher than from the rest of the well. These observations
confirm that magnetic microcapsules can be targeted with a
magnet with a consequent increase in transfection eﬃciency
at the localized site.
Fig. 1 Appearance and properties of magnetic microcapsules. Scanning
electron microscope images of a standard (A) and magnetic (B) bio-
degradable microcapsule. Sedimentation of microcapsules in 20 minutes
was monitored by the change in absorbance at 328 nm (C) with stan-
dard microcapsules (open circles) and magnetic microcapsules in the
absence (solid black circles) and presence of a magnetic ﬁeld (red
circles) shown. Toxicity of magnetic and standard microcapsules to
HeLa cells was also monitored (D). Cells were either untreated (Un) or
were exposed to microcapsules at ratios of 1 : 10 or 1 : 100 for 24 hours
(green bars), 48 hours (blue bars) or 72 hours (red bars). Values are the
mean of triplicate readings with the SEM shown by the error bar. Signiﬁ-
cant diﬀerences from the untreated cells of p ≤ 0.05 and p ≤ 0.01 are
shown by ★ and ★★, respectively.
Fig. 2 Improved luciferase enzyme delivery with magnetic micro-
capsules. Magnetic (M, solid circles) and standard (NM, open circles)
microcapsules with core luciferase were added to 293 T cells in 12 well
plates (150 000 per well) at a capsule to cell ratio of 10 : 1 and delivery
was monitored by real time bioluminescence imaging at time-points up
to 480 minutes (A). Light emission was quantitated with Living Image
software version 2.5.50.1 (B). Values are the mean of triplicate readings
and vertical lines are the standard error of the mean.
Fig. 3 Enhanced cell transfection with magnetic LbL microcapsules.
Microcapsules containing pcLuc+ plasmid DNA were added to cells
(30 000) in 96 well plates at ratios of 5 : 1 (A) and 10 : 1 (B). Cell lysates
were collected at 24, 48 and 72 hours after standard (open circle) and
magnetic (black circle) microcapsule delivery and luciferase activity in
the lysates was measured using a plate luminometer. Values are the
mean of triplicate readings and vertical lines are the standard error of
the mean.
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Discussion
In these studies we have revealed some interesting aspects of
cell delivery of bioactive molecules with magnetic LbL micro-
capsules. We know from other work that the initial interaction
between standard microcapsules and the cell surface is electro-
static and they are engulfed by a phagocytotic mechanism
utilising lipid-raft mediated macropinocytosis which targets
microcapsules into acidic heterophagolysosomes.27 The
increased sedimentation rate of magnetic microcapsules will
result in more rapid interaction with cells and potentially an
increased eﬃciency of cell delivery which results in improved
kinetics of luciferase delivery and cell transfection than
achieved with standard microcapsules. An interesting obser-
vation is the diﬀerence in enhancement of luciferase delivery
(×25) and cell transfection (×3.4) with magnetic microcapsules
(without a magnet) compared to standard microcapsules. The
improvement in cell uptake of microcapsules will be similar
for both cargoes so the diﬀerence in the magnitude of
enhanced activity (enzyme or transfection) must relate to their
Fig. 4 Magnetic targeting of luciferase microcapsules. 293T cells
(150 000 per well) were plated on a 24 well black walled tissue culture
plate. The next day magnetic microcapsules were added to triplicate
wells at ratios of 5, 2.5, 1.25 and 0.6125 per cell. At the time of addition
either a magnet was placed under the left half of the well (A) or no
magnet was used. After 300 minutes potassium luciferase substrate was
added to each well and a bioluminescent image was captured on the
large pixel setting for 10 minutes (B). Light emission from each well was
quantiﬁed using the grid template overlaid in B and light emission values
for the left and right sides of each well were calculated and mean values
of triplicate readings were plotted (C). Vertical lines represent the SEM
and signiﬁcant diﬀerences from the right-hand side of the well of
p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001 are indicated by ★, ★★ and ★★★,
respectively.
Fig. 5 Magnetically targeted microcapsule transfection. 293 T cells
(150 000 per well) were plated on a 24 well black walled tissue culture
plate. The next day magnetic microcapsules were added to quadru-
plicate wells at ratios of cell to microcapsules of 1 : 1 or 1 : 10. For indi-
cated wells, a small magnet (A) was placed under the left-hand side of
the well at the time of microcapsule addition and remained in place
throughout the course of the experiment. After 72 hours potassium luci-
ferase substrate was added to each well and a bioluminescent image was
captured on the small pixel setting for 30 seconds (B). Light emission
from each well was quantiﬁed using the template shown in B so that light
emission from the site of the magnet and the rest of the well (both
divided by area) were calculated. Mean values of quadruplicate readings
were plotted (C) with yellow bars indicating light from the theoretical site
of the magnet, red bars representing light from the actual site of the
magnet and green bars representing light from the rest of the well. Verti-
cal lines represent the SEM and signiﬁcant diﬀerences between the site of
the magnet and the rest of the well of p ≤ 0.005 are indicated by★.
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intracellular processing. Luciferase is an active molecule which
can provide signal whilst associated with the microcapsule
structure21 whereas plasmid DNA must be liberated from cap-
sules to enter the nucleus and proceed through transcription
and translation before enzyme activity of newly formed protein
can be monitored. We also know that plasmid DNA interacts
with polyarginine in an almost irreversible manner with the
polypeptide located in the DNA minor grove and polypeptide
side chains neutralizing phosphate charges of the DNA.28,29
Despite better delivery to cells it may well be that liberation of
plasmid DNA from microcapsules is impeded by its interaction
with this component of the microcapsule structure. Plasmid
DNA will also need to transit from the endosome to the cytosol
which should be facilitated by the proton sponge eﬀect of PEI.
Indeed we have previously used PEI for plasmid DNA delivery
from LbL microcapsules21 and similar microcapsules have uti-
lised PEI to promote delivery of siRNA to cells.30 Interestingly,
the incorporation of PEI into the microcapsule structure for
siRNA delivery resulted in a reduction in its toxicity to cells.30
The increased density alone enables more rapid interaction of
magnetic microcapsules with cells so it would be interesting to
examine alternative construction approaches that also result in
higher density microcapsules, to determine their influence on
delivery. Indeed, previous work has shown that increasing the
amount of complexed DNA at the cell surface through use of a
dense silica support results in increased transfection.31 In
essence mechanisms that improve cell microcapsule contact
could facilitate cell entry and combining cell interaction
approaches may have additive or synergistic eﬀects on cell
delivery.
There is a growing interest in the idea of magnetically tar-
geted delivery. Magnetofection has become an established
in vitro method for the delivery of plasmid DNA to cells32 and
recent studies have demonstrated magnetically targeted gene
transfection in vivo using magnetic liposomes33 or micro-
bubbles.34 Although magnetically targeted drug delivery is an
area of great interest35 the potential for delivery of therapeutic
proteins has not been explored. There have been reports on
the cellular delivery of BSA with both magnetic nanoparticles36
and magnetic microspheres37 but we are not aware of any pre-
vious reports on delivery of bioactive protein to cells. The
potential to use LbL microcapsules for magnetically targeted
delivery of protein therapeutics oﬀers a novel approach that
would be suited to intracellularly acting molecules. Toxins
could be a particularly suitable cargo if their positioning in
microcapsules could also render them inactive until appropri-
ate delivery in cells. Furthermore, the potential to deliver both
protein and DNA cargoes in a magnetically targeted manner
and from the same microcapsule illustrates the uniqueness
and versatility of the LbL microcapsule delivery approach.
The demonstration of navigated microcapsules with conse-
quent cell delivery to targeted cells is an important observation
of this study. We know that microcapsules can be targeted
with magnetism13,14 but here we show that cell delivery of two
cargoes is dramatically enhanced when microcapsules are tar-
geted with a magnet. The improved delivery is a consequence
of the increased microcapsule to cell ratio at the site of the
magnet. For targeted delivery of luciferase the concentration
eﬀect was two fold in area and the increase in activity was of
the same degree. Similarly, the concentration in the transfec-
tion experiment was 5.4 fold in area, and the increase in light
emission was approximately 7 fold when compared to the rest
of the well. Clearly navigation increases the ratio of micro-
capsules per cell but our toxicity data suggests that there are
limits to the extent to which this concentration can be safely
performed. Other studies have also noted cellular toxicity of
Fe3O4 nanoparticles
38,39 which was associated with increased
intracellular production of reactive oxygen species (ROS) along
with cytoplasmic vacuolation, mitochondrial swelling and
increased nitric oxide production. An interesting observation
with Fe2O3 nanoparticles was that the oxidative stress could be
prevented by treatment with ROS inhibitors,40 in LbL micro-
capsules, inhibitors could potentially be introduced into the
capsule structure.
In terms of navigation we know that a magnetic field can be
used to navigate microcapsules under flow conditions,11 so
this raises the possibility that systemic in vivo delivery with
magnetic targeting is feasible with guidance by magnetic reso-
nance as shown by Pouponneau et al.41 A prerequisite will be
to assess the suitability of LbL microcapsules for intravenous
delivery but success with similarly sized microbubbles
suggests that intravascular delivery of LbL microcapsules will
be feasible.
Although we have demonstrated improved delivery of bio-
active molecules alone and their targeted delivery with a
magnet there is the potential to further enhance magnetic
delivery through the use of an alternating magnetic field.
Potentially magnetic nanoparticles within the microcapsule
structure will vibrate in an alternating magnetic field and thus
increase the permeability of microcapsules or cause hyperther-
mic heating both of which will promote cargo release. Other
studies have demonstrated these eﬀects with magnetic nano-
particles in microcapsule layers.42–44
This study further informs us about the design of micro-
capsules for the delivery of bioactive molecules. The middle
layer which we have previously shown to be redundant for
delivery of bioactive molecules21 is shown here to be eﬀectively
used for inclusion of a physical property without impeding
delivery of the bioactive cargo from the capsule core. Indeed
the combination of functionalities (PEI coating for entry/endo-
somal escape promoter; magnetism for targeting/entry) in
microcapsules enhances the delivery. With further scope for
combining biological and physical activities, LbL assembled
microcapsules oﬀer an increasingly multifunctional delivery
approach for bioactive molecules which diﬀerentiates them
from other cell delivery systems.
Conclusions
In this work, intracellular delivery of an encapsulated enzyme
and plasmid DNA with magnetic microcapsules was studied.
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Inclusion of magnetite nanoparticles in LbL microcapsules
promoted enzyme and plasmid delivery to cells as a result of
their more rapid sedimentation rate and improved contact
with cells. In addition, magnetic microcapsules could be
eﬃciently navigated to cells with a magnet located below the
tissue culture well. In these guided experiments enhanced
activity was delivered to cells with both enzyme and DNA con-
taining LbL microcapsules.
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